JP2015017044A - 脂肪蓄積抑制及び/又は脂肪蓄積量低減剤 - Google Patents
脂肪蓄積抑制及び/又は脂肪蓄積量低減剤 Download PDFInfo
- Publication number
- JP2015017044A JP2015017044A JP2013143837A JP2013143837A JP2015017044A JP 2015017044 A JP2015017044 A JP 2015017044A JP 2013143837 A JP2013143837 A JP 2013143837A JP 2013143837 A JP2013143837 A JP 2013143837A JP 2015017044 A JP2015017044 A JP 2015017044A
- Authority
- JP
- Japan
- Prior art keywords
- fat accumulation
- fat
- amide
- beet
- amide compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009825 accumulation Methods 0.000 title claims abstract description 54
- 230000009467 reduction Effects 0.000 title abstract description 5
- 230000005764 inhibitory process Effects 0.000 title abstract description 4
- -1 phenolic amide compound Chemical class 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 12
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims abstract description 9
- 235000021536 Sugar beet Nutrition 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 5
- 235000016068 Berberis vulgaris Nutrition 0.000 description 44
- 241000335053 Beta vulgaris Species 0.000 description 44
- 150000001408 amides Chemical class 0.000 description 42
- 210000001789 adipocyte Anatomy 0.000 description 17
- 230000004069 differentiation Effects 0.000 description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 229940114124 ferulic acid Drugs 0.000 description 10
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 10
- 235000001785 ferulic acid Nutrition 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013332 fish product Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XWDDIZKKSZLMEB-UHFFFAOYSA-N Feruloyl tyramine Natural products COc1cc(C=CC(=O)Oc2ccc(CCN)cc2)ccc1O XWDDIZKKSZLMEB-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- NPNNKDMSXVRADT-WEVVVXLNSA-N N-feruloyltyramine Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)NCCC=2C=CC(O)=CC=2)=C1 NPNNKDMSXVRADT-WEVVVXLNSA-N 0.000 description 1
- AVBCARAQLFOQID-UHFFFAOYSA-N N-trans-feruloyltyramine Natural products COc1cc(C=CC(=O)CNCc2ccc(O)cc2)ccc1O AVBCARAQLFOQID-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- NPNNKDMSXVRADT-UHFFFAOYSA-N cis-N-feruloyl tyramine Natural products C1=C(O)C(OC)=CC(C=CC(=O)NCCC=2C=CC(O)=CC=2)=C1 NPNNKDMSXVRADT-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000001366 vegetable intake Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Abstract
Description
(1)下記化1で示されるフェノール性アミド化合物、及び/又は、下記化2で示されるフェノール性アミド化合物を有効成分としてなる脂肪蓄積抑制及び/又は脂肪蓄積量低減剤(言い換えれば、脂肪細胞中の中性脂肪蓄積抑制及び/又は中性脂肪蓄積量低減剤、更に言えば、脂肪細胞の肥大化及び/又は分化抑制剤)。
(2)フェノール性アミド化合物が甜菜由来であることを特徴とする、(1)に記載の剤。
(3)フェノール性アミド化合物が甜菜種子由来であることを特徴とする、(2)に記載の剤。
(4)1食当たりの単位包装形態からなり、該単位中に、フェノール性アミド化合物を5〜600mg含有することを特徴とする、(1)〜(3)のいずれか1つに記載の剤。
(5)5〜600mg/日のフェノール性アミド化合物が、ヒトに対して1日1回経口摂取されるように用いられることを特徴とする、(1)〜(3)のいずれか1つに記載の剤。
(6)(1)の化1及び/又は化2で示されるフェノール性アミド化合物を5〜600mg含有する飲食品を経口的に継続摂取させることを特徴とする、脂肪蓄積抑制及び/又は脂肪蓄積量低減方法(ヒトに対する医療行為を除く)。
ビートアミド1及びビートアミド2の取得は、以下のようにして行った。
実施例1で取得したビートアミド1、ビートアミド2の生理活性をフェルラ酸と比較確認するため、以下の試験を実施した。
Claims (6)
- フェノール性アミド化合物が甜菜由来であることを特徴とする、請求項1に記載の剤。
- フェノール性アミド化合物が甜菜種子由来であることを特徴とする、請求項2に記載の剤。
- 1食当たりの単位包装形態からなり、該単位中に、フェノール性アミド化合物を5〜600mg含有することを特徴とする、請求項1〜3のいずれか1項に記載の剤。
- 5〜600mg/日のフェノール性アミド化合物が、ヒトに対して1日1回経口摂取されるように用いられることを特徴とする、請求項1〜3のいずれか1項に記載の剤。
- 請求項1の化3及び/又は化4で示されるフェノール性アミド化合物を5〜600mg含有する飲食品を経口的に継続摂取させることを特徴とする、脂肪蓄積抑制及び/又は脂肪蓄積量低減方法(ヒトに対する医療行為を除く)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013143837A JP6161438B2 (ja) | 2013-07-09 | 2013-07-09 | 脂肪蓄積抑制及び/又は脂肪蓄積量低減剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013143837A JP6161438B2 (ja) | 2013-07-09 | 2013-07-09 | 脂肪蓄積抑制及び/又は脂肪蓄積量低減剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015017044A true JP2015017044A (ja) | 2015-01-29 |
JP6161438B2 JP6161438B2 (ja) | 2017-07-12 |
Family
ID=52438412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013143837A Active JP6161438B2 (ja) | 2013-07-09 | 2013-07-09 | 脂肪蓄積抑制及び/又は脂肪蓄積量低減剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6161438B2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018510890A (ja) * | 2015-04-09 | 2018-04-19 | ガルデルマ・ソシエテ・アノニム | インジゴ・ナチュラリス由来のエキス及びそれを調製する方法 |
US10555985B2 (en) | 2015-04-09 | 2020-02-11 | Galderma S.A. | Pharmaceutical composition comprising refined Indigo naturalis extracts and the use thereof |
US10668120B2 (en) | 2015-04-09 | 2020-06-02 | Galderma Sa | Antibacterial indigo naturalis or indigo-producing plant extract and use thereof |
CN111757743A (zh) * | 2018-01-10 | 2020-10-09 | 布莱特西德公司 | 用于调节代谢的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000129257A (ja) * | 1998-10-27 | 2000-05-09 | Nippon Beet Sugar Mfg Co Ltd | 植物性抗酸化剤、及び、胃潰瘍等治療薬 |
JP2005225872A (ja) * | 2004-01-15 | 2005-08-25 | National Institute Of Advanced Industrial & Technology | アディポネクチン産生増進剤 |
WO2005095414A1 (ja) * | 2004-03-31 | 2005-10-13 | Suntory Limited | アディポネクチン上昇剤 |
JP2008291002A (ja) * | 2007-05-28 | 2008-12-04 | House Wellness Foods Kk | メタボリックシンドロームの予防、改善または治療組成物 |
JP2011148748A (ja) * | 2010-01-25 | 2011-08-04 | Shirako:Kk | アディポネクチン分泌促進組成物 |
-
2013
- 2013-07-09 JP JP2013143837A patent/JP6161438B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000129257A (ja) * | 1998-10-27 | 2000-05-09 | Nippon Beet Sugar Mfg Co Ltd | 植物性抗酸化剤、及び、胃潰瘍等治療薬 |
JP2005225872A (ja) * | 2004-01-15 | 2005-08-25 | National Institute Of Advanced Industrial & Technology | アディポネクチン産生増進剤 |
WO2005095414A1 (ja) * | 2004-03-31 | 2005-10-13 | Suntory Limited | アディポネクチン上昇剤 |
JP2008291002A (ja) * | 2007-05-28 | 2008-12-04 | House Wellness Foods Kk | メタボリックシンドロームの予防、改善または治療組成物 |
JP2011148748A (ja) * | 2010-01-25 | 2011-08-04 | Shirako:Kk | アディポネクチン分泌促進組成物 |
Non-Patent Citations (3)
Title |
---|
LIFE SCI. 2008, VOL.82, NO.5-6, PP.290-300, JPN6017006638, ISSN: 0003508489 * |
LIFE SCI. 2011, VOL.88, NO.13-14, PP.613-618, JPN6017006639, ISSN: 0003508490 * |
NEW FOOD INDUSTRY, 2006, VOL.48, NO.11, PP1-14, JPN7017000701, ISSN: 0003508491 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018510890A (ja) * | 2015-04-09 | 2018-04-19 | ガルデルマ・ソシエテ・アノニム | インジゴ・ナチュラリス由来のエキス及びそれを調製する方法 |
US10555985B2 (en) | 2015-04-09 | 2020-02-11 | Galderma S.A. | Pharmaceutical composition comprising refined Indigo naturalis extracts and the use thereof |
US10668120B2 (en) | 2015-04-09 | 2020-06-02 | Galderma Sa | Antibacterial indigo naturalis or indigo-producing plant extract and use thereof |
US10695391B2 (en) | 2015-04-09 | 2020-06-30 | Galderma S.A. | Extract from Indigo Naturalis and a process for preparing the same |
US11116811B2 (en) | 2015-04-09 | 2021-09-14 | Galderma S.A. | Pharmaceutical composition comprising refined indigo naturalis extracts and the use thereof |
CN111757743A (zh) * | 2018-01-10 | 2020-10-09 | 布莱特西德公司 | 用于调节代谢的方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6161438B2 (ja) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101982326B1 (ko) | 근육 질환 예방, 개선 또는 치료용 또는 근 기능 개선용 조성물 | |
JP6564134B2 (ja) | モルシン、クワノンジ又は桑白皮を含有する筋肉疾患予防及び治療用又は筋機能改善用組成物 | |
JP6161438B2 (ja) | 脂肪蓄積抑制及び/又は脂肪蓄積量低減剤 | |
KR101760512B1 (ko) | 혼합 생약 추출물을 포함하는 만성 염증성 질환의 예방, 치료 또는 개선용 조성물 | |
US11612629B2 (en) | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient | |
JP2016199491A (ja) | 気分状態改善剤 | |
JP5711616B2 (ja) | Il−17産生抑制剤 | |
JP2014208600A (ja) | ウコン中の有用成分を含有する組成物 | |
JP2008074745A (ja) | 血糖上昇抑制剤 | |
JP2007230987A (ja) | 抗肥満剤 | |
JP2012131760A (ja) | 脂肪酸吸収抑制剤 | |
JP2013075831A (ja) | 新規ヒドロキシスチルベン誘導体 | |
KR101719015B1 (ko) | 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
JP6861139B2 (ja) | セロトニン代謝抑制剤、飲食品組成物、及び、医薬品 | |
JP2012206964A (ja) | PPAR−α活性調節剤 | |
JP7117763B2 (ja) | 経口組成物 | |
WO2021112263A1 (ja) | アディポネクチン産生促進剤 | |
JP2007230989A (ja) | 持久力増強・抗疲労剤 | |
JP2003286181A (ja) | アトピー性皮膚炎易発症体質改善剤 | |
JP2002080357A (ja) | 高血圧症予防・改善・治療剤 | |
KR20210157502A (ko) | 배초향 추출물 또는 틸리아닌를 유효성분으로 함유하는 근육 질환 개선, 치료 또는 예방용, 또는 근 기능 개선용 조성물 | |
JP2021016363A (ja) | 脂質分解促進剤及びこれを含む飲食品、並びに脂質分解促進用加工食品 | |
KR20210158444A (ko) | 자바투메릭 또는 잔소리졸을 유효성분으로 함유하는 근육 질환 개선, 치료 또는 예방용, 또는 근 기능 개선용 조성물 | |
JP2023069459A (ja) | サイクリックampホスホジエステラーゼ活性阻害剤 | |
JP2013177340A (ja) | 抗炎症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170424 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6161438 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |